Mortality and Disease Severity Among COVID-19 Patients Receiving Renin-Angiotensin System Inhibitors: A Systematic Review and Meta-analysis

DiscussionSince there was no increased risk of harm, the use of RAS inhibitors for hypertension and other established clinical indications can be maintained in COVID-19 patients.

http://link.springer.com/10.1007/s40256-020-00439-5

Source: American Journal of Cardiovascular Drugs - September 11, 2020 Category: Cardiology Source Type: research